Elsevier

Clinical Therapeutics

Volume 26, Issue 2, February 2004, Pages 191-196
Clinical Therapeutics

Review article
Topical antibacterial therapy for mycobacterial keratitis: Potential for surgical prophylaxis and treatment

https://doi.org/10.1016/S0149-2918(04)90018-5Get rights and content

Abstract

Background:Mycobacterium chelonae and Mycobacterium fortuitum are the 2 most commonly implicated species of nontuberculous myoobacteria in cases of bacterial keratitis.

Objectives: This article summarizes available data on the in vitro antibacterial activity against M chelonae or M fortuitum of 2 agents—amikacin and clarithromycin—that have been used in the treatment of bacterial keratitis. In addition, the article reviews the in vitro activity of 5 commercially available topical ocular fluoro-quinolones (in order of availability, ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin) that may have potential in the surgical prophylaxis and treatment of keratitis caused by M chelonae or M fortuitum.

Methods: A search of the English-language literature indexed on the MEDLINE, Life Sciences, EMBASE, BIOSIS, and Pharmaprojects databases from 1966 to October 7, 2003, was conducted using the terms Mycobacterium chelonae, Mycobacterium fortuitum, bacterial keratitis, topical antibiotic therapy, ocular infection-mycobacteria, and LASIK infections. Data on the minimum concentrations at which 90% of isolates were inhibited (MIC90s) were reviewed and compared.

Results: In the literature reviewed, the MIC90 against M fortuitum was from 1 to 16 μg/mL for amikacin, from ≤2 to ≥8 μg/mL for clarithromycin, from 0.1 to 1 μg/mL for ciprofloxacin, from 0.5 to 3.13 μg/mL for ofloxacin, and ≤2 μg/mL for levofloxacin. The results were similar against M chelonae. The fourth-generation fluoroquinolones—gatifloxacin and moxifloxacin—had similar MIC90s against M fortuitum (both, 0.2 to 1 μg/mL); however, moxifloxacin had greater activity than gatifloxacin against M chelonae (minimum inhibitory concentration range: moxifloxacin, ≤1 to 1.6 μg/mL; gatifloxacin, 3.2 to 6.25 μg/mL).

Conclusions: Topical fluoroquinolones may be beneficial for ocular surgical prophylaxis and for the treatment of keratitis caused by M chelonae or M fortuitum. Based on their reported MIC90s, none of the antibacterials reviewed had greater in vitro activity than moxifloxacin. In addition, moxifloxacin had greater in vitro activity than gatifloxacin against M chelonae, one of the predominant nontuberculous mycobacterial species involved in bacterial keratitis. Pending the conduct of controlled clinical studies, these findings suggest that moxifloxacin may have utility in the prevention and treatment of atypical mycobacterial keratitis.

References (32)

  • A. Matoba

    Mycobacterium chelonae keratitis

    Am J Ophthalmol

    (1987)
  • S.C. Huang et al.

    Nontuberculous mycobacterial keratitis: A study of 22 cases

    Br j Ophthalmol

    (1996)
  • P.R. Gangadharam et al.

    Keratitis due to Mycobacterium chelonei

    Tubercle

    (1978)
  • C.E. Margo et al.

    Mycobacterium chelonae conjunctivitis and scleritis following vitrectomy

    Arch Ophthalmol

    (2000)
  • N. Pushker et al.

    Microbial keratitis after laser in situ keratomileusis

    J Refract Surg

    (2002)
  • C.H. Hsiao et al.

    Intrascleral dissemination of infectious scleritis following pterygium excision

    Br j Ophthalmol

    (1998)
  • Cited by (53)

    • Discovery of novel antimycobacterial drug therapy in biofilm of pathogenic nontuberculous mycobacterial keratitis

      2017, Ocular Surface
      Citation Excerpt :

      Therefore, we investigated the fate of mycobacteria in a murine model of corneal infection and report our findings herein. Medical treatments of NTM infections are often unsuccessful, possibly due to biofilm formation [24] or variable in vitro antibiotic sensitivities for different strains of NTM [26]. Amikacin has been the agent of choice for treatment of most NTM infections and may be a clinical gold standard [27].

    • Mycobacteriological characteristics and treatment outcomes in extrapulmonary Mycobacterium abscessus complex infections

      2017, International Journal of Infectious Diseases
      Citation Excerpt :

      The most common causative organism is Mycobacterium chelonae, with MABC accounting for 10% of NTM ocular infections (Kheir et al., 2015). Some patients recover fully after antibiotic treatment, whereas others need therapeutic surgical interventions (Kheir et al., 2015), and unlike other extrapulmonary NTM infections, NTM ocular infections can be successfully treated with topical antibiotics (Abshire et al., 2004). MABC is traditionally considered to be resistant to multiple antibiotics, and data supporting effective drugs or regimens are very limited.

    • Oral moxifloxacin and topical amikacin for Mycobacterium abscessus keratitis after laser in situ keratomileusis

      2010, Journal of Cataract and Refractive Surgery
      Citation Excerpt :

      The normal host defense against this organism is thought to be strong because exposure is universal and related disease rare.2 Mycobacterium abscessus keratitis after LASIK is a severe infection with a frequently delayed diagnosis, slow resolution, and difficult treatment that often involves the need for surgical intervention (eg, lamellar keratoplasty, flap removal, flap irrigation with antibiotic agents).3 This is due to the highly invasive nature of the pathogen, which has the ability to deeply penetrate the collagen layers of the cornea.

    View all citing articles on Scopus
    View full text